Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

Although today's B-OM initial results are only based on preliminary and limited data, my enthusiasm has greatly increased for many reasons.

In particular, patient recruitment as we know has likely been challenging for possible many reasons:

Patients are aware that there chance of receiving the placebo is 50%, other oral mucositis trials in past have mostly been unsuccessful, current trial is not by a major pharmaceutical company, trial is only a phase 2 with no previous known efficacy, trial sites were initially limited.

However, now that we are armed with initial encouraging results - radiation oncologists, oncologists, and patients can be made aware and this will undoubtedly help recruitment efforts. Moreover, the recent expansion of additional clinical sites should definitely speed along the current trial.

I congratulate and continue to appreciate the efforts of Cellceutix management on behalf of shareholders and look forward to more excellent news!